双重免疫疗法为复发/难治性霍奇金淋巴瘤增添价值。 - Suppr

Suppr

超能文献

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma.

作者信息

Hallam Simon

机构信息

St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.

出版信息

Hemasphere. 2018 Jul 26;2(4):e137. doi: 10.1097/HS9.0000000000000137. eCollection 2018 Aug.

DOI:10.1097/HS9.0000000000000137

PMID:31723786

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6745997/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da16/6745997/85d4051d52de/hs9-2-e137-g001.jpg

相似文献

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma.双重免疫疗法为复发/难治性霍奇金淋巴瘤增添价值。

Hemasphere. 2018 Jul 26;2(4):e137. doi: 10.1097/HS9.0000000000000137. eCollection 2018 Aug.

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.双特异性 T 细胞衔接器（BiTE）抗体构建药物blinatumomab 治疗复发/难治性非霍奇金淋巴瘤患者：I 期研究的最终结果。

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结

Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比

Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.

Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.复发难治性霍奇金淋巴瘤中的肿瘤相关巨噬细胞。

Leuk Res. 2013 Sep;37(9):1178-83. doi: 10.1016/j.leukres.2013.03.021. Epub 2013 May 21.

High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm.高剂量化疗及自体干细胞移植治疗复发或难治性霍奇金淋巴瘤：新出现的问题、新型药物及不断变化的模式

Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):272-276. doi: 10.1016/j.hemonc.2017.05.010. Epub 2017 Jun 13.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.抗 CD79B 抗体药物偶联物 polatuzumab vedotin 在复发或难治性 B 细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病中的安全性和活性：一项 1 期研究。

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.放疗联合纳武单抗治疗复发/难治性经典型霍奇金淋巴瘤：附两例病例

Cancer Radiother. 2019 Jun;23(3):232-239. doi: 10.1016/j.canrad.2018.12.005. Epub 2019 May 27.

Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.纳武利尤单抗致复发/难治性霍奇金淋巴瘤细胞因子释放综合征：一例报告及文献复习。

Immunotherapy. 2018 Aug;10(11):913-917. doi: 10.2217/imt-2018-0025.

Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.移植前氟代脱氧葡萄糖正电子发射断层扫描在接受自体干细胞移植治疗的难治性/复发性霍奇金淋巴瘤中的预后价值：系统评价和荟萃分析

Ann Hematol. 2016 Apr;95(5):695-706. doi: 10.1007/s00277-016-2619-9. Epub 2016 Mar 2.

引用本文的文献

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.复发/难治性经典型霍奇金淋巴瘤中的检查点抑制剂

World J Oncol. 2021 Aug;12(4):81-84. doi: 10.14740/wjon1388. Epub 2021 Jul 10.

Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.移植不合格的复发或难治性经典型霍奇金淋巴瘤的检查点抑制疗法

JCO Oncol Pract. 2021 Feb;17(2):64-71. doi: 10.1200/OP.20.00771. Epub 2021 Jan 12.

本文引用的文献

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.本妥昔单抗维布妥昔单抗联合纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的初步结果。

Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。

Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.PET 适应序贯挽救治疗，采用 Brentuximab Vedotin 继以增强异环磷酰胺、卡铂和依托泊苷，用于复发和难治性霍奇金淋巴瘤患者：一项非随机、开放标签、单中心、2 期研究。

Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验